Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots

Shots: The United States has about 38.4 million people living with diabetes, representing 11.6% of the total population. With growing prevalence, there is a significant unmet need for affordable diabetes medications. Biocon Biologics recently announced the FDA approval of Kirsty, the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Joshua Salsi, the Head of…

BySaurabh ChaubeySeptember 8, 2025

Biocon Biologics’ Kirsty (Biosimilar, NovoLog) Secures the US FDA’s Approval

Shots: The US FDA has approved Kirsty (100 units/mL), an interchangeable biosimilar of NovoLog (Insulin Aspart) to improve glycemic control in adults & pediatric pts with diabetes mellitus Approval was based on comprehensive analytical, non-clinical, & clinical data, which showed similar efficacy, safety, purity & potency of Kirsty vs NovoLog Kirsty is a rapid-acting human…

ByRidhi RastogiJuly 16, 2025

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

Shots: With an incurable nature and hefty medication costs, diabetes mellitus remains a global health concern and the seventh leading cause of death across the world. The 2021 data reflects 537M affected people, with the predominant population living in low- and middle-income countries Type 2 diabetes mellitus (T2DM), unlike Type 1 diabetes mellitus (T1DM) is…

BySaurabh ChaubeyApril 13, 2023

Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots

Biocon Biologics’ Kirsty (Biosimilar, NovoLog) Secures the US FDA’s Approval

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

Contact US

OUR INFORMATION

FOLLOW US